ANS is committed to advancing, fostering, and promoting the development and application of nuclear sciences and technologies to benefit society.
Explore the many uses for nuclear science and its impact on energy, the environment, healthcare, food, and more.
Explore membership for yourself or for your organization.
Conference Spotlight
2026 ANS Annual Conference
May 31–June 3, 2026
Denver, CO|Sheraton Denver
Latest Magazine Issues
Mar 2026
Jul 2025
Latest Journal Issues
Nuclear Science and Engineering
March 2026
Nuclear Technology
February 2026
Fusion Science and Technology
April 2026
Latest News
NRC approves TerraPower construction permit
Today, the Nuclear Regulatory Commission announced that it has approved TerraPower’s construction permit application for Kemmerer Unit 1, the company’s first deployment of Natrium, its flagship sodium fast reactor.
This approval is a significant milestone on three fronts. For TerraPower, it represents another step forward in demonstrating its technology. For the Department of Energy, it reflects progress (despite delays) for the Advanced Reactor Demonstration Program (ARDP). For the NRC, it is the first approval granted to a commercial reactor in nearly a decade—and the first approval of a commercial non–light water reactor in more than 40 years.
George A. Miller, Jr., Nolan E. Hertel, Bernard W. Wehring, John L. Horton
Nuclear Technology | Volume 103 | Number 3 | September 1993 | Pages 320-331
Technical Paper | Radiation Biology and Medicine | doi.org/10.13182/NT93-A34855
Articles are hosted by Taylor and Francis Online.
A computer study of the dose distribution for gadolinium neutron capture therapy is carried out to determine its feasibility. Gadolinium is a potential neutron capture therapy (NCT) agent that produces gamma radiation, conversion electrons, and Auger electrons. The dose distribution from neutrons, neutron-induced gammas, and the reaction products from neutron capture in gadolinium were modeled using the Los Alamos National Laboratory Monte Carlo neutron photon computer code. The results of these calculations are that gadolinium has promise as an NCT agent. Using two parallel opposed epithermal neutron beams for a tumor at an 8.0-cm depth with a gadolinium loading of 100 µg/g, the tumor to peak normal tissue dose was determined to be 1.48.